SCHEMBL126745

SCHEMBL126745

CCCCCCCCCC#CO

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN7 P35236 5/20 0.52
HMGCR P04035 3/20 0.52
RECQL P46063 2/20 0.47
TDP1 Q9NUW8 2/20 0.47
TSHR P16473 2/20 0.44
THRB P10828 1/20 0.44
MEN1 O00255 2/20 0.43
ALDH1A1 P00352 2/20 0.43
KMT2A Q03164 2/20 0.43
KDM4E B2RXH2 1/20 0.43
USP2 O75604 1/20 0.43
POLB P06746 1/20 0.43
MAPT P10636 1/20 0.43
HPGD P15428 1/20 0.43
ALOX12 P18054 1/20 0.43
BLM P54132 1/20 0.43
MCL1 Q07820 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
LMNA P02545 2/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL129776 1.00 PTPN7 (0.52) PTPN7HMGCRRECQLTDP1TSHR
SCHEMBL130214 1.00 PTPN7 (0.52) PTPN7HMGCRRECQLTDP1TSHR
SCHEMBL9361038 1.00 PTPN7 (0.52) PTPN7HMGCRRECQLTDP1TSHR
SCHEMBL448226 1.00 PTPN7 (0.52) PTPN7HMGCRRECQLTDP1TSHR
SCHEMBL128297 1.00 PTPN7 (0.52) PTPN7HMGCRRECQLTDP1TSHR
SCHEMBL448860 1.00 PTPN7 (0.52) PTPN7HMGCRRECQLTDP1TSHR
SCHEMBL448474 1.00 PTPN7 (0.52) PTPN7HMGCRRECQLTDP1TSHR
SCHEMBL128390 1.00
SCHEMBL130583 1.00 PTPN7 (0.52) PTPN7HMGCRRECQLTDP1TSHR
SCHEMBL31423438 1.00 PTPN7 (0.52) PTPN7HMGCRRECQLTDP1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0365149-A2 Leukotriene antagonist prodrugs SMITHKLINE BEECHAM CORPORATION (US) 1990-04-25 EP claimed
EP-2300224-B1 ARTICLES CONTAINING FUNCTIONAL POLYMERIC PHASE CHANGE MATERIALS AND METHODS OF MANUFACTURING THE SAME OUTLAST TECH GMBH (DE) 2024-09-11 EP disclosed
EP-2300658-B1 HEAT REGULATING ARTICLE WITH MOISTURE ENHANCED TEMPERATURE CONTROL OUTLAST TECH GMBH (DE) 2024-08-14 EP disclosed
US-20240125678-A1 COMPOUND, CELLULAR VESICLE STAIN, AND METHOD FOR FLUORESCENT STAINING OF CELLULAR VESICLES NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (JP) 2024-04-18 US disclosed
WO-2024053316-A1 COMPOUND, EXTRACELLULAR VESICLE STAINING AGENT, AND FLUORESCENT STAINING METHOD FOR EXTRACELLULAR VESICLES 国立大学法人東海国立大学機構 2024-03-14 WO disclosed
EP-4286388-A1 COMPOUND, CELLULAR VESICLE STAIN, AND METHOD FOR FLUORESCENT STAINING OF CELLULAR VESICLES National University Corporation Tokai National Higher Education and Research System (JP) 2023-12-06 EP disclosed
EP-2362830-B1 MICROCAPSULES AND OTHER CONTAINMENT STRUCTURES FOR ARTICLES INCORPORATING FUNCTIONAL POLYMERIC PHASE CHANGE MATERIALS OUTLAST TECH GMBH (DE) 2023-09-20 EP disclosed
EP-2883865-B1 Compound capable of binding S1P receptor and pharmaceutical use thereof ONO PHARMACEUTICAL CO (JP) 2019-09-25 EP disclosed
EP-2740724-B1 COMPOUND FOR TREATING CARTILAGE DISORDERS ONO PHARMACEUTICAL CO (JP) 2016-12-28 EP disclosed
EP-2657229-B1 BENZYLOXYPYRIMIDINE DERIVATIVE, AGRICULTURAL/HORTICULTURAL INSECTICIDE COMPRISING SAID DERIVATIVE AND METHOD FOR USING THE SAME NIHON NOHYAKU CO LTD (JP) 2016-03-30 EP disclosed
US-5719176-A 2-amino-1,3-propanediol compound and immunosuppressant YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1998-02-17 US disclosed
US-5646273-A FOR USE IN OPTICAL DISKS MITSUI TOATSU CHEMICALS, INC. (JP) 1997-07-08 US disclosed
EP-0781827-A1 Liquid crystal mixture and liquid crystal device comprising the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1997-07-02 EP disclosed
US-5604229-A 2-amino-1,3-propanediol compound and immunosuppressant YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1997-02-18 US disclosed
EP-0709444-A1 Liquid crystal mixture and liquid crystal device comprising the same SUMITOMO CHEMICAL COMPANY LIMITED (JP) 1996-05-01 EP disclosed
EP-0627406-A1 2-AMINO-1,3-PROPANEDIOL COMPOUND AND IMMUNOSUPPRESSANT YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1994-12-07 EP disclosed
EP-0619345-A1 Phthalocyanine compound and optical recording medium containing it MITSUI TOATSU CHEMICALS, Inc. (JP) 1994-10-12 EP disclosed
EP-0365149-A3 LEUKOTRIENE ANTAGONIST PRODRUGS SMITHKLINE BEECHAM CORPORATION (US) 1990-07-25 EP disclosed
EP-0365149-A2 Leukotriene antagonist prodrugs SMITHKLINE BEECHAM CORPORATION (US) 1990-04-25 EP disclosed
EP-0365149-A2 Leukotriene antagonist prodrugs SMITHKLINE BEECHAM CORPORATION (US) 1990-04-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240125678-A1 COMPOUND, CELLULAR VESICLE STAIN, AND METHOD FOR FLUORESCENT STAINING OF CELLULAR VESICLES EXOSC4, EXOSC5, EXOSC9 PTPN7 4035/4885HMGCR 3221/4885RECQL 1783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.